Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.35, MarketWatch Earnings reports. The business had revenue of $16.82 million during the quarter, compared to the consensus estimate of $17.05 million. Aquestive Therapeutics updated its FY 2019 guidance to EPS.

Shares of NASDAQ:AQST traded up $0.15 on Friday, hitting $6.52. The stock had a trading volume of 650 shares, compared to its average volume of 114,662. Aquestive Therapeutics has a twelve month low of $5.60 and a twelve month high of $20.70. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.42 and a current ratio of 3.63.

Several institutional investors have recently added to or reduced their stakes in the stock. Crestline Management LP acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth $201,422,000. Perceptive Advisors LLC bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $20,137,000. Alliancebernstein L.P. bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $14,323,000. BlackRock Inc. bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $8,254,000. Finally, Vanguard Group Inc bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $8,055,000. 58.34% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 25th. BMO Capital Markets decreased their target price on shares of Aquestive Therapeutics to $21.00 and set an “outperform” rating for the company in a report on Friday. Finally, Lake Street Capital reiterated a “buy” rating on shares of Aquestive Therapeutics in a report on Wednesday, February 20th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $23.60.

WARNING: This piece of content was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://theolympiareport.com/2019/03/15/aquestive-therapeutics-aqst-issues-earnings-results.html.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Recommended Story: Understanding Specialty Certificates of Deposit

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.